Abstract

Methamphetamine (METH) is a highly addictive psychostimulant with no therapeutics registered to assist addicts in discontinuing use. Glutamatergic dysfunction has been implicated in the development and maintenance of addiction. We sought to assess the involvement of the metabotropic glutamate 5 receptor (mGlu5) in behaviours relevant to METH addiction because this receptor has been implicated in the actions of other drugs of abuse, including alcohol, cocaine and opiates. mGlu5 knockout (KO) mice were tested in intravenous self-administration, conditioned place preference and locomotor sensitization. Self-administration of sucrose was used to assess the response of KO mice to a natural reward. Acquisition and maintenance of self-administration, as well as the motivation to self-administer METH was intact in mGlu5 KO mice. Importantly, mGlu5 KO mice required more extinction sessions to extinguish the operant response for METH, and exhibited an enhanced propensity to reinstate operant responding following exposure to drug-associated cues. This phenotype was not present when KO mice were tested in an equivalent paradigm assessing operant responding for sucrose. Development of conditioned place preference and locomotor sensitization were intact in KO mice; however, conditioned hyperactivity to the context previously paired with drug was elevated in KO mice. These data demonstrate a role for mGlu5 in the extinction and reinstatement of METH-seeking, and suggests a role for mGlu5 in regulating contextual salience.

Highlights

  • Methamphetamine (METH) is a highly addictive psychostimulant for which there are currently no approved pharmacotherapies to treat abusers [1,2]

  • We examined the response of metabotropic glutamate 5 receptor (mGlu5) KO mice to a natural reward in an operant paradigm, to delineate possible differences in extinction and reinstatement for METH and a natural reward

  • A significant interaction [F(1,35) = 7.1, p = .01] suggests a greater increase in preference score in which met reinstatement criteria (WT) compared to mGlu5 KO mice; one-way analysis of variance (ANOVA) split by ‘genotype’ demonstrates a significant increase in preference score in both genotypes [WT: F(1,14) = 28.5, p,.001; mGlu5 KO: F(1,21) = 25.6, p,.001; Fig. 1a]

Read more

Summary

Introduction

Methamphetamine (METH) is a highly addictive psychostimulant for which there are currently no approved pharmacotherapies to treat abusers [1,2]. Overwhelming evidence from rodent models suggests chronic drug use results in the dysregulation of the glutamatergic system [4,5,6,7,8]; for reviews see [3,9,10,11]) This is reflected in human imaging studies, which reveal reduced brain glutamate concentrations in frontal white and grey matter in recently abstinent METH users [12,13,14,15]. There is some support for this in preliminary human studies in drug addicts; N-acetylcysteine administration (which restores glutamate homeostasis) reduces cocaine craving in addicts [19], N- acetylcysteine combined with naltrexone for METH dependence has no effect on METH use or craving. While there may be a role for glutamate dysfunction in METH addiction (e.g. [12,13,20,21]), the nature of this dysfunction requires further investigation

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call